

## Scientific Poster Presentations, III

Wednesday, October 24

Great Halls 4–6

8:00 a.m.–10:00 a.m.

### ENCORE PRESENTATIONS

Abstracts marked with an “E” are Encore Presentations. Encore Presentations undergo the same peer-review process as all other presentations, but they may have been presented elsewhere or published in abstract form before the 2012 Annual Meeting. For presentations, the abstract title, authors, and original citation (if provided) are published.

### ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoconomics, and pharmacoepidemiology.

#### Cardiovascular

22E. Impact of a High-Fat Meal on Assessment of Clopidogrel-Induced Platelet Inhibition in Healthy Subjects.

*Paul P. Dobesh, Pharm.D.,<sup>1</sup> Jamela Urban, Pharm.D.,<sup>2</sup> Scott Shurmur, M.D.,<sup>2</sup> Julie H. Oestreich, Pharm.D.<sup>1</sup>;* (1)University of Nebraska Medical Center, Omaha, NE; (2)The Nebraska Medical Center, Omaha, NE

23. Perceptions, Knowledge, and Patterns of Use of “Fish Oil” Products in Cardiac Patients.

*Elizabeth B. Hawkins, Pharm.D.,<sup>1</sup> Hua Ling, Pharm.D.,<sup>2</sup> Tammy L. Burns, Pharm.D.,<sup>2</sup> Daniel E. Hilleman, Pharm.D., FCCP<sup>3</sup>;* (1)Creighton University Medical Center, Omaha, NE; (2)Creighton University Cardiac Center, Creighton University School of Medicine, Omaha, NE; (3)Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE

24. Aliskiren in Patients Failing to Achieve Blood Pressure Targets with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.

*Elizabeth B. Hawkins, Pharm.D.,<sup>1</sup> Hua Ling, Pharm.D.,<sup>2</sup> Tammy L. Burns, Pharm.D.,<sup>2</sup> Aryan Mooss, M.D.,<sup>2</sup> Daniel E. Hilleman, Pharm.D., FCCP<sup>3</sup>;* (1)Creighton University Medical Center, Omaha, NE; (2)Creighton University Cardiac Center, Creighton University School of Medicine, Omaha, NE; (3)Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE

25. Discordance Between Regression-Derived and ATP III Table-Derived Framingham 10-Year Risk: A P.A.T.H. Substudy.

*Steven M. Smith, Pharm.D., MPH,<sup>1</sup> Nancy Borja-Hart, Pharm.D.,<sup>2</sup> Audrey Wooten, M.D.,<sup>3</sup> Benjamin J. Epstein, Pharm.D.,<sup>4</sup>;* (1)University of Colorado, Aurora, CO; (2)East Coast Institute for Research, Jacksonville, FL; (3)St. Vincent’s Hospital, Jacksonville, FL; (4)University of Florida, Gainesville, FL

26. Impact of Safety Alerts on Prescribing Patterns of Simvastatin and Atorvastatin in an Outpatient Cardiac Specialty Centre in Singapore.

*Chai Ling Ong, BSPHarm(Hons), Jacqueline Peck Sze Wong, BSPHarm(Hons), Shera See Ah Wong, BSPHarm(Hons), Huey Shyan Yong, BSPHarm(Hons), Jin Shing Hon, BSPHarm(Hons), Siew Chong Teo,*

MSP Pharm (Clin Pharm), Chi Keong Ching, FAMS (Cardiology); National Heart Centre Singapore, Singapore, Singapore

27. Effectiveness and Safety of Rivaroxaban Compared to Enoxaparin for Thromboprophylaxis in Orthopedic Patients.

*Vimala Sivapragasam, Pharm.D., BCPS, Teena Abraham, Pharm.D., BCPS, Nasser Saad, Pharm.D., Henry Tischler, M.D., Eric Balmir, Pharm.D.*; New York Methodist Hospital, Brooklyn, NY

28. The Relative Bioavailability of Single-Dose Rivaroxaban, a Novel Oral Anticoagulant and a Selective Direct Factor Xa Inhibitor, Administered Orally (as a whole or crushed tablet) and via Nasogastric Tube (as a crushed tablet suspension).

*Kenneth T. Moore, M.S.,<sup>1</sup> Seema Vaidyanathan, M.S.,<sup>1</sup> Chandrasekharrao V. Damaraju, Ph.D.,<sup>2</sup> Larry E. Fields, M.D., MBA, FAHA, FACC<sup>3</sup>*; (1)Janssen Research & Development, LLC, Titusville, NJ; (2)Janssen Research & Development, LLC, Raritan, NJ; (3)Janssen Scientific Affairs, LLC, Raritan, NJ

29. Factors Influencing Physicians' Selection of Dabigatran in Non-valvular Atrial Fibrillation.

*Cindy Huang, Pharm.D., Michele Siu, Pharm.D., Lily Vu, Pharm.D., Soo Wong, Pharm.D., Jaekyu Shin, Pharm.D.*; University of California at San Francisco, San Francisco, CA

30. Comparison of the Risk of Bradycardia Between Two Oral Metoprolol Formulations.

*Jaekyu Shin, Pharm.D.,<sup>1</sup> Marco Gonzales, Pharm.D.,<sup>2</sup> Mark Pletcher, M.D.<sup>1</sup>*; (1)University of California at San Francisco, San Francisco, CA; (2)California Department of Health Care Services, Sacramento, CA

31. Heart Failure Patients Demographics at an Inner City Safety Net Hospital.

*Andrew Smith, Pharm.D.,<sup>1</sup> Darcy Green-Conaway, M.D.,<sup>2</sup> Mark E. Patterson, Ph.D., MPH<sup>3</sup>*; (1)UMKC School of Pharmacy, Kansas City, MO; (2)Truman Medical Center, Kansas City, MO; (3)University of Missouri–Kansas City School of Pharmacy, Kansas City, MO

32. Impact of Worsening Renal Function on Resource Utilization and Medications After Diuretic Dose Escalation in a Chronic Heart Failure Ambulatory Population.

*Vicki L. Groo, Pharm.D.,<sup>1</sup> Anita Lammers, Pharm.D.,<sup>2</sup> Daniel Touchette, Pharm.D., M.A.,<sup>1</sup> Thomas D. Stamos, M.D.<sup>1</sup>*; (1)University of Illinois at Chicago, Chicago, IL; (2)Illinois Masonic Medical Center, Chicago, IL

33. Baseline Albumin Predicts Worsening Renal Function in Acute Decompensated Heart Failure Patients Receiving Continuous Infusion Loop Diuretics.

*Megan M. Barnes, Pharm.D., BCPS,<sup>1</sup> Michael P. Dorsch, Pharm.D., M.S., BCPS (AQ-CV),<sup>2</sup> Susie Kim, Pharm.D.,<sup>3</sup> Keith Aaronson, M.D., M.S.,<sup>2</sup> Todd Koelling, M.D.,<sup>2</sup> Barry E. Bleske, Pharm.D., FCCP<sup>4</sup>*; (1)Allegheny General Hospital, Pittsburgh, PA; (2)University of Michigan Hospitals and Health Centers, Ann Arbor, MI; (3)Eli Lilly & Company, Indianapolis, IN; (4)University of Michigan, Ann Arbor, MI

34E. Stability of Levosimendan During Simulated Y-Site Administration.

*Wayne S. Moore II, Pharm.D.,<sup>1</sup> Jeffrey J. Cies, Pharm.D., BCPS,<sup>2</sup> Michael A. McCulloch, M.D.,<sup>1</sup> Deborah A. Davis, M.D.,<sup>1</sup> Robert W. Mason, Ph.D.<sup>3</sup>*; (1)Alfred I. duPont Hospital for Children/Nemours Cardiac Center, Wilmington, DE; (2)St. Christopher's Hospital for Children, Philadelphia, PA; (3)Alfred I. duPont Hospital for Children/Nemours Biomedical Research, Wilmington, DE

35. The Effect of Continuous-Infusion Loop Diuretics in Acute Decompensated Heart Failure Patients with Hypoalbuminemia.

*Michael P. Dorsch, Pharm.D., M.S., BCPS (AQ-CV),<sup>1</sup> Megan M. Barnes, Pharm.D.,<sup>2</sup> Audrey H. Wu, M.D.,<sup>1</sup> Barry E. Bleske, Pharm.D., FCCP<sup>3</sup>*; (1)University of Michigan Hospitals and Health Centers, Ann Arbor, MI; (2)Allegheny General Hospital, Pittsburgh, PA; (3)University of Michigan, College of Pharmacy, Ann Arbor, MI

36. The Effects of Universal Fibrate Discontinuation on Management of Dyslipidemia at the Portland Veterans Affairs Medical Center (PVAMC).

*Mariah D. Alford, Pharm.D.,<sup>1</sup> Jessina C. McGregor, Ph.D.,<sup>2</sup> Harleen Singh, Pharm.D.<sup>2</sup>*; (1)Portland Veterans Affairs Medical Center, Portland, OR; (2)Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, OR

37. A Pilot Feasibility Study to Assess Knowledge and Behaviors Related to Warfarin Therapy.

*Kathryn M. Momary, Pharm.D., BCPS, Nicole L. Metzger, Pharm.D., BCPS, Kevin Sponsel, Pharm.D. Candidate, Annette Daehler, Pharm.D. Candidate*; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

38. The Effects of Carvedilol in Patients with Cocaine-Induced Chest Pain.

*Shannon W. Finks, Pharm.D.,<sup>1</sup> Corry T. Johnston, Pharm.D.,<sup>2</sup> Robert B. Parker, Pharm.D.,<sup>1</sup> Kelly C. Rogers, Pharm.D.<sup>1</sup>*; (1)University of Tennessee College of Pharmacy, Memphis, TN; (2)Veterans Affairs Medical Center, Memphis, TN

40. Racial Differences in Anticoagulation Control and Risk of Hemorrhage Among Warfarin Users.

*Jonathan L. Thigpen, Pharm.D.,<sup>1</sup> Qi Yan, M.S.,<sup>2</sup> Nianjun Liu, Ph.D.,<sup>3</sup> Mark Beasley, Ph.D.,<sup>3</sup> Nita A. Limdi, Pharm.D., Ph.D.<sup>1</sup>*; (1)University of Alabama at Birmingham, Department of Neurology, Birmingham, AL; (2)University of Alabama at Birmingham, School of Public Health, Birmingham, AL; (3)University of Alabama at Birmingham, Department of Biostatistics, Birmingham, AL

## **Clinical Administration**

42. Balance of Academic Responsibilities of Clinical Track Pharmacy Faculty in the US.

*Edith A. Nutescu, Pharm.D., Robert DiDomenico, Pharm.D., Sacheeta Bathija, BPharm, Shellee Grim, Pharm.D., Jeffrey Mucksavage, Pharm.D., Eljim Tesoro, Pharm.D., Kirsten Ohler, Pharm.D., James Thielke, Pharm.D., Juliana Chan, Pharm.D., Nancy Shapiro, Pharm.D., Janet Engle, Pharm.D.*; University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice, Chicago, IL

## **Education/Training**

49. Student Performance and Faculty Perception After Transition to Team-Based Learning in a Drug-Induced Disease Elective.

*Sarah A. Treadway, Pharm.D., BCPS,<sup>1</sup> Michelle Z. Farland, Pharm.D., BCPS,<sup>2</sup> Shaunta' Ray, Pharm.D., BCPS<sup>2</sup>*; (1)Auburn University Harrison School of Pharmacy, Mobile, AL; (2)University of Tennessee College of Pharmacy, Knoxville, TN

50. Use of a Unified Learning Style Model to Improve Student Self-Directed Learning in Pharmacy Students.

*Christopher A. Giuliano, Pharm.D., Jessica L. Jones, Pharm.D., Emily T. Martin, MPH, Ph.D., Vickie Poremba, Pharm.D. Candidate, Lynette R. Moser, Pharm.D.*; Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI

51. Tracking the Development of Student Self-Efficacy to Perform Clinical Pharmacy Tasks.

*Stuart T. Haines, Pharm.D., BCPS, David Roffman, Pharm.D., BCPS, Lisa Lebovitz, J.D., Deborah A. Sturpe, Pharm.D., BCPS*; University of Maryland School of Pharmacy, Baltimore, MD

52. Academic Workload: What the Heck Are We Doing?

*Kamila A. Dell, Pharm.D., BCPS, Marianne E. Koenig, Pharm.D., BCPS, Erini S. Serag, Pharm.D., Amanda M. DeBruin, Pharm.D., BCPS, CGP, Jose L. Barboza, Pharm.D., Aimon C. Miranda, Pharm.D., Shyam R. Gelot, Pharm.D., L. Douglas Ried, Ph.D.*; University of South Florida College of Pharmacy, Tampa, FL

53. Attitudes and Perceptions of Postgraduate Residents and Fellows in Telemedicine Services at the University of Illinois at Chicago College of Pharmacy.  
*Melissa E. Badowski, Pharm.D.*, Chessa R. Nyberg, Pharm.D.; University of Illinois at Chicago, Chicago, IL
54. An Evaluation of Student Drug Literature Evaluation Skills by Comparing Student Performance on Journal Club Presentations and Application-Based Biostatistics Questions.  
*Jean E. Cunningham, Pharm.D.*, Laura Perry, Pharm.D.; The University of Findlay College of Pharmacy, Findlay, OH
55. Facebook Activity and Views Regarding E-professionalism: A Survey of Pharmacy Students in Qatar.  
*Maguy S. El Hajj, Pharm.D.*, Tasnim Abd Al Halim Massoud, BSP Pharm Candidate, Atefeh Gholamhussain Moeinzadeh, BSP Pharm Candidate; Qatar University College of Pharmacy, Doha, Qatar
56. Students' Perceptions of the Effect of Pharmacotherapeutics Workshops on Clinical Skills Practiced on Advanced Pharmacy Practice Experiences.  
Jennifer J. D'Souza, Pharm.D., BC-ADM, CDE,<sup>1</sup> *Kathy E. Komperda, Pharm.D., BCPS*,<sup>1</sup> Jill S. Borchert, Pharm.D., FCCP, BCPS,<sup>1</sup> Jacob P. Gettig, Pharm.D., MPH, BCPS,<sup>1</sup> Meri Hix, Pharm.D., BCPS, CGP,<sup>2</sup> Tudy Hodgman, Pharm.D., FCCM, BCPS,<sup>1</sup> Timothy Todd, Pharm.D.<sup>1</sup>; (1)Midwestern University Chicago College of Pharmacy, Downers Grove, IL; (2)Texas Tech University Health Sciences Center School of Pharmacy, Abilene, TX
57. Evaluation of Improved Evidence-Based Patient Care Application During a Primary Care Advanced Practice Experience.  
*Kelly Hester, Pharm.D., BCPS, AAHIVE*,<sup>1</sup> Dana G. Carroll, Pharm.D.,<sup>2</sup> Kristi Kelley, Pharm.D., BCPS, CDE<sup>3</sup>; (1)Auburn University Harrison School of Pharmacy, Auburn, AL; (2)Auburn University Harrison School of Pharmacy, Tuscaloosa, AL; (3)Auburn University, Harrison School of Pharmacy, Birmingham, AL
- 58E. Evaluation of Clinical Skills with an Objective Structured Clinical Examination.  
Elizabeth M. Urteaga, Pharm.D., *Rebecca Attridge, Pharm.D., M.S., BCPS*, John Tovar, Pharm.D., Amy Witte, Pharm.D.; University of the Incarnate Word – Feik School of Pharmacy, San Antonio, TX
59. Standardized Approach to Patient-Based Pharmacotherapy Notes in a Therapeutics Course.  
*Angela O. Shogbon, Pharm.D., BCPS*, Lisa M. Lundquist, Pharm.D., BCPS, Kathryn M. Momary, Pharm.D., BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA
60. Student Perceptions of Team-Based Learning Activities in a Critical Care Elective as Preparation for Advanced Practice Pharmacy Experiences.  
*Katie E. Ronald, Pharm.D.*; Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, IL
61. Development and Evaluation of a Team-Taught Academic Advanced Pharmacy Practice Experience (APPE).  
*Sandra Benavides, Pharm.D.*,<sup>1</sup> Antonia Zapantis, Pharm.D., M.S.,<sup>1</sup> Jehan Marino, Pharm.D.,<sup>1</sup> Jennifer G. Steinberg, Pharm.D.,<sup>1</sup> Elizabeth Sherman, Pharm.D.,<sup>1</sup> Angela S. Garcia, Pharm.D.,<sup>1</sup> Nancy Borja-Hart, Pharm.D.,<sup>2</sup> Joshua Caballero, Pharm.D.<sup>1</sup>; (1)Nova Southeastern University, College of Pharmacy, Davie, FL; (2)East Coast Institute for Research, Jacksonville, FL
62. Impact of a Residency Interviewing Preparatory Seminar (RIPS) Elective in Securing Post-doctoral Training.  
*Joshua Caballero, Pharm.D.*,<sup>1</sup> Sandra Benavides, Pharm.D.,<sup>1</sup> Kevin A. Clauson, Pharm.D.,<sup>2</sup> Jennifer G. Steinberg, Pharm.D.,<sup>1</sup> Timothy P. Gauthier, Pharm.D.,<sup>1</sup> Shara Elrod, Pharm.D.,<sup>1</sup> Jehan Marino, Pharm.D.<sup>1</sup>; (1)Nova Southeastern University, College of Pharmacy, Davie, FL; (2)Nova Southeastern University, College of Pharmacy – West Palm Beach, USA, Palm Beach Gardens, FL

63. Patient Care Impact and Potential Cost Avoidance Generated by Student Pharmacists During Advanced Pharmacy Practice Experiences.  
*Adam B. Woolley, Pharm.D., BCPS*, Roger A. Edwards, ScD, Charles A. Berds IV, BSPHarm, Margarita V. DiVall, Pharm.D., BCPS; Northeastern University School of Pharmacy, Boston, MA
64. Use of Pre- and Post-tests to Assess Student Pharmacist Effectiveness When Presenting In-services to Other Health Care Professionals.  
*Amber N. McLendon, Pharm.D.*,<sup>1</sup> C. Brock Woodis, Pharm.D.<sup>2</sup>; (1)Campbell University College of Pharmacy and Health Sciences and Glenaire, Inc. CCRC, Buies Creek, NC; (2)Campbell University College of Pharmacy and Health Sciences and Duke University Department of Community and Family Medicine, Durham, NC
65. The Impact of Objective Structured Clinical Examination on Pharmacy Intern Training Program.  
*Shu-Hsien Wu, B.S.*, Yun-Ting Pan, B.S., Ming-Shya Wan, M.S., Shu-Hui Sun, M.S.; Department of Pharmacy, Far Eastern Memorial Hospital, New Taipei City, Taiwan
66. Interventions by Student Pharmacists in an Outpatient Teaching Family Medicine Center.  
*Miranda R. Andrus, Pharm.D., BCPS*, T. Lynn Stevenson, Pharm.D., BCPS, CDM; Auburn University Harrison School of Pharmacy, Auburn, AL
67. Impact of a Virtual Patient Pilot Program on Student Pharmacists' Learning Outcomes.  
*Mark A. Douglass, Pharm.D.*,<sup>1</sup> Jillian Casale, Pharm.D. Candidate,<sup>2</sup> Margarita V. DiVall, Pharm.D., BCPS,<sup>2</sup> J. Andrew Skirvin, Pharm.D., BCOP<sup>2</sup>; (1)Northeastern University Department of Pharmacy Practice/Boston Medical Center, Boston, MA; (2)Northeastern University School of Pharmacy, Boston, MA
68. Evaluation of a Strategy to Build Competency in a Drug Literature Evaluation Course.  
*Shannon Reidt, Pharm.D., MPH*, Kristin K. Janke, Ph.D., Jenifer L. Morgan, Pharm.D.; University of Minnesota College of Pharmacy, Minneapolis, MN
69. Teaching HIV Management to Pharmacy Students: Taking the Clinic to the Classroom.  
*Lisa Inge, Pharm.D., BCPS, BCACP, AAHIVE*; University of Florida, College of Pharmacy, Jacksonville, FL
70. Student Use of Insulin Pumps as an Empathy Exercise.  
*Ashley W. Ellis, Pharm.D., BCACP*,<sup>1</sup> Matthew Strum, Pharm.D., BCACP, CDE,<sup>2</sup> Anastasia B. Jenkins, Pharm.D.,<sup>3</sup> John Bentley, Ph.D., MBA, B.S.<sup>2</sup>; (1)University of Mississippi, University, TN; (2)University of Mississippi School of Pharmacy, University, MS; (3)University of Mississippi, University, MS
71. Research Competencies and Preparedness Among Hospital Practicing Pharmacists in Qatar.  
*Ahmed Awaisu, Ph.D.*,<sup>1</sup> Dana Bakdach, BSPHarm,<sup>1</sup> Reem H. Elajej, BSPHarm,<sup>1</sup> Manal Al Zaidan, BSPHarm<sup>2</sup>; (1)College of Pharmacy, Qatar University, Doha, Qatar; (2)Heart Hospital and NCCCR, Hamad Medical Corporation, Doha, Qatar
72. The State of Nuclear Pharmacy Education in ACPE-Accredited Colleges of Pharmacy.  
*Edward M. Bednarczyk, Pharm.D.*, Samuel Miller, Pharm.D., Mark Sauberan, B.S.; University at Buffalo, Buffalo, NY
73. Clinical Communication Skills Compared with Written and Oral Examination Performance.  
Lisa M. Lundquist, Pharm.D., BCPS, *Angela O. Shogbon, Pharm.D., BCPS*, Kathryn M. Momary, Pharm.D., BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA
74. Communication of Clinical Recommendations During Oral Examinations.  
Lisa M. Lundquist, Pharm.D., BCPS, *Angela O. Shogbon, Pharm.D., BCPS*, Kathryn M. Momary, Pharm.D., BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA
- 75E. Evaluation of Pharmacy Students' Clinical Interventions on Advanced Pharmacy Practice Experiences at a Non-teaching Hospital.

*Angela O. Shogbon, Pharm.D., BCPS, Lisa M. Lundquist, Pharm.D., BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA*

76. Student Pharmacists' Perception of a Service Learning Experience at a Charity Pharmacy.  
*Lauren S. Bloodworth, Pharm.D., BCPS, Meagan Brown, Pharm.D., Courtney Davis, Pharm.D., Leigh Ann Ross, Pharm.D., BCPS; University of Mississippi School of Pharmacy, Jackson, MS*

77. Incorporation of Human Patient Simulation into an Antimicrobial Stewardship–Based Infectious Diseases Elective.  
*Bonnie A. Falcione, Pharm.D., BCPS (AQ-ID), Susan M. Meyer, Ph.D., Amy L. Seybert, Pharm.D., FASHP, FCCP; University of Pittsburgh School of Pharmacy, Pittsburgh, PA*

78. SOAP Note Written Documentation Needs Assessment and Course Methodology Evaluation for On-line Course.  
*Ann M. Snyder, Pharm.D.; Pharmacotherapy & Translational Research, University of Florida, Gainesville, FL*

## **Emergency Medicine**

79. Etomidate vs. Non-etomidate Induction for Rapid Sequence Intubation in Trauma.  
*Elizabeth Hand, Pharm.D.,<sup>1</sup> Michael Corneille, M.D.,<sup>2</sup> Kay Green, R.Ph., BCPS,<sup>1</sup> Pam Maxwell, Pharm.D., BCPS,<sup>1</sup> Darrel W. Hughes, Pharm.D., BCPS<sup>1</sup>; (1)University Health System, San Antonio, TX; (2)UTHSCSA, San Antonio, TX*

80. Intravenous Sodium Bicarbonate Therapy in Severely Acidotic Diabetic Ketoacidosis.  
*Bryson Duhon, Pharm.D.,<sup>1</sup> Ana Crystal Franco-Martinez, Pharm.D., BCPS,<sup>1</sup> Rebecca Attridge, Pharm.D., M.S., BCPS,<sup>2</sup> Pam Maxwell, Pharm.D., BCPS,<sup>1</sup> Darrel W. Hughes, Pharm.D., BCPS<sup>1</sup>; (1)University Health System, San Antonio, TX; (2)University of the Incarnate Word – Feik School of Pharmacy, San Antonio, TX*

82. Hypotension Associated with Propofol in Trauma Patients in the Emergency Department.  
*Amanda E. Shearin, Pharm.D., Asad E. Patanwala, Pharm.D., Andrew Tang, M.D., Brian L. Erstad, Pharm.D.; University of Arizona, Tucson, AZ*

83. From Sunset to Sunrise: The Role and Potential Value of Newly Established Night-shift Emergency Department Pharmacists in a Community Regional Medical Center.  
*Sandra C. Bartlett, Ph.D., Pharm.D., BCPS, Brooke M. Bitner, Pharm.D., Katherine E. Burenheide, Pharm.D., M.S., BCPS; Stormont-Vail HealthCare, Topeka, KS*

## **Endocrinology**

84. Pharmacist-Led Diabetes Chronic Care Management Program Improves Glycemic Control Without Increasing Costs in Patients with Uncontrolled Type 2 Diabetes.  
*Carrie McAdam-Marx, Ph.D., R.Ph.,<sup>1</sup> Brandon T. Jennings, Pharm.D.,<sup>2</sup> Arati Dahal, Ph.D.,<sup>1</sup> Karen Gunning, Pharm.D.,<sup>3</sup>; (1)University of Utah Pharmacotherapy Outcomes Research Center, Salt Lake City, UT; (2)University of Utah College of Pharmacy, Salt Lake City, UT; (3)University of Utah Departments of Pharmacotherapy & Family and Preventive Medicine, Salt Lake City, UT*

85E. Evaluation of the Use of Different Insulin Regimens in the Treatment of Type 1 and Type 2 Diabetes Mellitus.  
*Maha Mahmoud Al Hakim, MSPHarm,<sup>1</sup> Abobakr Abasaeed, Pharm.D.,<sup>2</sup> D. Jones, Professor<sup>3</sup>; (1)Mafrag Hospital, Inpatient Pharmacy, Drug Information Centre, Abu Dhabi, UAE, Abu Dhabi, United Arab Emirates; (2)Ministry of Health, Abu Dhabi, United Arab Emirates; (3)Queen University, Belfast, United Kingdom*

86. Impact of an Interdisciplinary Inpatient Diabetes Education Process on Patient Understanding and Adherence.

Amanda Lin, Pharm.D.,<sup>1</sup> Kim C. Coley, Pharm.D.,<sup>2</sup> Rima A. Mohammad, Pharm.D.,<sup>2</sup> Amy C. Donihi, Pharm.D.<sup>2</sup>; (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

87. A Retrospective Analysis of Vitamin D Practice Patterns in a Veterans Affairs Medical Center.

Elizabeth A. Connolly, Pharm.D.,<sup>1</sup> Debra W. Kemp, Pharm.D., BCPS, BCACP,<sup>2</sup> Karen Barnard, M.D.<sup>3</sup>; (1)UNC Eshelman School of Pharmacy, Chapel Hill, NC; (2)UNC Eshelman School of Pharmacy/Durham VA Medical Center, Durham, NC; (3)Durham VA Medical Center, Durham, NC

## Geriatrics

91. Opportunities for Quality Improvement in Long-term Care (LTC): Medication-Related Contributors to Falls Among Older Residents of a Retirement Community.

Carlos Rojas-Fernandez, Pharm.D.,<sup>1</sup> Susan G. Brown, M.S.,<sup>2</sup> Josie d'Avernas, M.S.<sup>2</sup>; (1)University of Waterloo School of Pharmacy/Schlegel-UW Research Institute for Aging, Kitchener, ON, Canada; (2)Schlegel-UW Research Institute for Aging, Kitchener, ON, Canada

93. Results of a Pharmacist-Managed Anticoagulation Service at a Long-term Care Facility.

Haley M. Phillippe, Pharm.D.; Harrison School of Pharmacy, Brownsboro, AL

## Health Services Research

95. Effectiveness of a Pharmacy Care Management Program for Veterans with Dyslipidemia.

Michael C. Smith, Pharm.D.,<sup>1</sup> Amy S. Boldt, Pharm.D.,<sup>1</sup> Cassandra M. Walston, Pharm.D.,<sup>1</sup> Alan J. Zillich, Pharm.D.<sup>2</sup>; (1)Richard L. Roudebush VA Medical Center, Indianapolis, IN; (2)Purdue University College of Pharmacy, Indianapolis, IN

96. Self-Control by Patients of the Medication List Compared to Medication Verification with Pharmacist.

Anders Ekedahl, Ph.D.; Medical Products Agency, Uppsala, Sweden

97E. Characterizing Financial Burden of Pulmonary Hypertension Within an Integrated Healthcare Delivery System.

Samuel G. Johnson, Pharm.D., BCPS (AQ Cardiology), Adrian Larkin, Pharm.D., Paul B. Shaw, Pharm.D., BCPS, Thomas Delate, Ph.D.; Kaiser Permanente, Aurora, CO

## Hematology/Anticoagulation

98. Quality and Outcomes Assessment of Intravenous Unfractionated Heparin Anticoagulation in Venous Thromboembolism.

Christine P. Rash, Pharm.D.,<sup>1</sup> Ruchi Patel, Pharm.D., BCPS,<sup>1</sup> Keri Bicking, Pharm.D., BCPS, BCNSP,<sup>1</sup> Luigi Brunetti, Pharm.D., MPH, BCPS, CGP,<sup>2</sup> Brian Faley, Pharm.D., BCPS,<sup>2</sup> Zachariah Thomas, Pharm.D., BCPS,<sup>2</sup> Massimo Napolitano, M.D.<sup>1</sup>; (1)Hackensack University Medical Center, Hackensack, NJ; (2)Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ

99. Impact of Platelet Functional Assays on the Cost of Treating Suspected Heparin-Induced Thrombocytopenia (HIT).

Ziad Sadik, Pharm.D., Douglas L. Jennings, Pharm.D., BCPS (AQ-CV), Carrie W. Nemerovski, Pharm.D., BCPS (AQ-CV), James S. Kalus, Pharm.D., BCPS (AQ-CV); Henry Ford Hospital, Detroit, MI

101E. Evaluating Standardized Weight-Based Heparin Nomogram vs. Patient-Specific Dosing to Achieve and Maintain Targeted Activated Partial Thromboplastin Time (aPTT) at a Quaternary Care Teaching Hospital.

*Leslie Varikattu, Pharm.D., Samrah Ahmad, Pharm.D., Rehana Jamali, Pharm.D.; North Shore University Hospital, Manhasset, NY*

102. Adverse Events in Patients Initiated on Dabigatran Etxilate Therapy in a Pharmacist-Managed Anticoagulation Clinic.

*Mark Donaldson, Pharm.D., BSP, FASHP, FACHE, Amber Norbeck, Pharm.D.; Kalispell Regional Medical Center, Kalispell, MT*

103. Effect of Patient Self-Testing on Chronic Anticoagulation.

*Cindy Leslie A. Arocena, Pharm.D., Stacey Dean, Pharm.D., BCPS; Virginia Commonwealth University Health System, Richmond, VA*

## **Nutrition**

149E. Omega-3 Long-Chain Polyunsaturated Fatty Acids Attenuate Bile Acid-Induced Apoptosis via Fas-Dependent Pathways.

*Emma M. Tillman, Pharm.D.,<sup>1</sup> Richard A. Helms, Pharm.D.,<sup>2</sup> Dennis D. Black, M.D.<sup>1</sup>; (1)University of Tennessee Health Science Center, Memphis, TN; (2)University of Tennessee, Memphis, TN*

## **Oncology**

151. Correlation of EGFR (Epidermal Growth Factor Receptor) Mutation Status with Gefitinib Response Rate Used as Second-line Therapy in Patient with Metastatic Non-Small Cell Lung Cancer.

*Sagar pravinchandra Kansara, MSPHarm; A.R. College of Pharmacy and Hemato-oncology Clinic, Vedanta Institute of Medical Sciences, Ahmedabad, India*

152E. Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Elderly (Age  $\geq$  60) Newly Diagnosed or Relapsed/Refractory Adult Patients with AML.

*Casey B. Williams, Pharm.D., BCOP,<sup>1</sup> Suman Kambhampati, M.D.,<sup>2</sup> Siddhartha Ganguly, M.D.,<sup>2</sup> Omar Aljitiawi, M.D.,<sup>2</sup> Jo Wick, Ph.D.,<sup>2</sup> Ruben Reyes, M.D.,<sup>2</sup> Allan Fleming, M.D.,<sup>2</sup> Kapil Bhalla, M.D.,<sup>2</sup> Sunil Abhyankar, M.D.,<sup>2</sup> Joseph McGuirk, D.O.<sup>2</sup>; (1)Sanford Research/USD, Sioux Falls, SD; (2)University of Kansas Medical Center, Kansas City, KS*

153. Efficacy of Single-Dose Rasburicase in Prophylaxis and Treatment of Tumor Lysis Syndrome: A Meta-analysis.

*Xiaodong Feng, Ph.D., Pharm.D., Kevin Dong, Pharm.D. Student, Dan Pham, Pharm.D. Student, John Inciardi, Pharm.D., D.Sci., Nilesh Bhutada, Ph.D.; California Northstate University College of Pharmacy, Rancho Cordova, CA*

154E. An Evaluation of the Incidence of Proteinuria and Hypertension in Patients Receiving Shorter Infusions of Bevacizumab.

*Sachin R. Shah, Pharm.D., BCOP,<sup>1</sup> Sarah M. Gressett Ussery, Pharm.D., BCOP<sup>2</sup>; (1)Texas Tech University Health Sciences Center School of Pharmacy/VA North Texas Health Care System, Dallas, TX; (2)Bristol-Myers Squibb, Waxahachie, TX*

155. Pilot Study: Valproic Acid Effectiveness in Minimizing Incidence of Seizures in Postoperative Pediatric Brain Tumor Patients.

*Sherif Kamal, Director of Department of Pharmaceutical Service,<sup>1</sup> Maggie M. Abbassi, Ph.D.,<sup>2</sup> Sherif Abouelnaga, Ph.D.,<sup>3</sup> Azza M. Agha, Ph.D.<sup>4</sup>; (1)Children Cancer Hospital Egypt 57357, Cairo, Egypt;*



(2)Faculty of Pharmacy, Cairo, Egypt; (3)Children Cancer Hospital Egypt, Cairo, Egypt; (4)Faculty of Pharmacy, Cairo, Egypt

156. High-Dose Bolus Interleukin-2: Correlating Response Rate with Number of Doses Received.  
*Jolly Patel, Pharm.D.*, Dawn Goetz, Pharm.D., BCOP, Mayer Fishman, M.D., Ph.D., Ragini Kudchadkar, M.D.; H. Lee Moffitt Cancer Center, Tampa, FL

158. Obesity and Carboplatin Dosing in Gynecologic Oncology Patients.  
Cory R. Bivona, Pharm.D.,<sup>1</sup> Susan Klenke, R.Ph., BCOP,<sup>1</sup> Gary Johnson, M.D.,<sup>2</sup> *Casey B. Williams, Pharm.D., BCOP*<sup>3</sup>; (1)University of Kansas Hospital, Kansas City, KS; (2)University of Kansas Cancer Center, Kansas City, KS; (3)Sanford Research/USD, Sioux Falls, SD

## Pharmacoepidemiology

183. A Descriptive Analysis of Medication Adherence and Mortality Among Elderly Post-MI Patients.  
Tasneem Lokhandwala, M.S., *Matthew Strum, Pharm.D., BCACP, CDE*, Yi Yang, M.D., Ph.D., John Bentley, Ph.D., B.S., MBA, Benjamin Banahan III, Ph.D.; University of Mississippi School of Pharmacy, University, MS

184. Identification of Adverse Drug Events Post-Hospital Discharge in a Geriatric Population.  
*Jennifer L. Donovan, Pharm.D.*,<sup>1</sup> Abir O. Kanaan, Pharm.D.,<sup>1</sup> Jennifer Tjia, M.D., MSCE,<sup>2</sup> Terry S. Field, DSc,<sup>3</sup> Shawn Gagne, B.S.,<sup>2</sup> Lawrence Garber, M.D.,<sup>4</sup> Sarah L. Cutrona, M.D., MPH,<sup>2</sup> Leslie R. Harrold, M.D., MPH,<sup>2</sup> Peggy Preusse, RN,<sup>4</sup> George Reed, Ph.D.,<sup>5</sup> Jerry H. Gurwitz, M.D.<sup>2</sup>; (1)Massachusetts College of Pharmacy and Health Sciences, Worcester, MA; (2)Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA; (3)Meyers Primary Care Institute, Worcester, MA; (4)Reliant Medical Group, Worcester, MA; (5)University of Massachusetts medical School, Worcester, MA

185. Cardiovascular Thromboembolic Events Associated with Use of Febuxostat: Investigation of Case Reports from the FDA Adverse Event Reporting System Database.  
Pranav K. Gandhi, Ph.D., William M. Gentry, Pharm.D., *Michael Bottorff, Pharm.D., FCCP, FNLA, CLS*; South College School of Pharmacy, Knoxville, TN

186. Identification of Bleeding Adverse Events Associated with the Concurrent Administration of Dabigatran and Dronedaron: Investigation of Case Reports from the FDA Adverse Event Reporting System Database.  
Pranav K. Gandhi, Ph.D., William M. Gentry, Pharm.D., *Michael Bottorff, Pharm.D., FCCP, FNLA, CLS*; South College School of Pharmacy, Knoxville, TN

187E. Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae in Community Hospitals: A Case-control Study.  
*Grace C. Lee, Pharm.D., BCPS*,<sup>1</sup> Donna R. Burgess, R.Ph.,<sup>2</sup> Kurt R. Winkler, Pharm.D., MHA, BCPS,<sup>3</sup> David S. Burgess, Pharm.D., FCCP<sup>1</sup>; (1)University of Texas at Austin College of Pharmacy and University of Texas Health Science Center School of Medicine, San Antonio, TX; (2)Methodist Hospital Department of Pharmacy and University of Texas at Austin College of Pharmacy, San Antonio, TX; (3)Methodist Hospital Department of Pharmacy, San Antonio, TX

## Pharmacogenomics

190. Association Between *CYP2C9* Genetic Polymorphism and the Pharmacokinetics and Pharmacodynamics of Glipizide.  
*Byung-Sung Kang, Ph.D. Candidate*, Hye-In Lee, M.S., Chang-Ik Choi, Ph.D.; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

191. Drug-Drug Interaction Between Pramipexole and Cimetidine, an OCT2 Inhibitor.

*Byung-Sung Kang, Ph.D. Candidate, Hye-In Lee, M.S., Chang-Ik Choi, Ph.D.; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea*

199. CYP2C9 Genotype-Dependent Inhibition of Gastric Acid Secretion by Omeprazole.

*So-Young Park, B.S.,<sup>1</sup> Chang-Ik Choi, Ph.D.,<sup>1</sup> Jung-Woo Bae, Ph.D.<sup>2</sup>; (1)School of Pharmacy, Sungkyunkwan University, Suwon, South Korea; (2)College of Pharmacy, Keimyung University, Daegu, South Korea*

200. Dose Optimization of Omeprazole According to the CYP2C19 Genotype.

*So-Young Park, B.S.,<sup>1</sup> Jung-Woo Bae, Ph.D.,<sup>2</sup> Chang-Ik Choi, Ph.D.<sup>1</sup>; (1)School of Pharmacy, Sungkyunkwan University, Suwon, South Korea; (2)College of Pharmacy, Keimyung University, Daegu, South Korea*

## **Psychiatry**

219E. Effects of Pharmacist Drug Regimen Reviews on Physicians' Compliance with Recommended Laboratory Monitoring Criteria for Psychotropic Medications at a State-Supported Living Center.

*Abimbola Farinde, Pharm.D., M.S., BCPP, CGP; Clear Lake Regional Medical Center, Webster, TX*

220E. Second-Generation Antipsychotic Prescribing Patterns for Veterans with Posttraumatic Stress Disorder over a Ten-Year Period.

*Marshall E. Cates, Pharm.D., FASHP, BCPP,<sup>1</sup> Lori L. Davis, M.D.,<sup>2</sup> Ekaette E. Ebong, Pharm.D.,<sup>2</sup> Joette S. Lowe, Pharm.D.<sup>2</sup>; (1)Samford University McWhorter School of Pharmacy, Birmingham, AL; (2)VA Medical Center, Tuscaloosa, AL*

## **Substance Abuse/Toxicology**

224E. Tapentadol Abuse: The First 18 Months.

*Richard C. Dart, M.D., Ph.D.,<sup>1</sup> Edgar H. Adams, ScD,<sup>2</sup> Becki B. Bucher-Bartelson, Ph.D.,<sup>1</sup> Gary M. Baker, Pharm.D.,<sup>3</sup> Janet K. Pitner, Pharm.D., MBA,<sup>3</sup> Gary J. Vorsanger, M.D., Ph.D.<sup>3</sup>; (1)Rocky Mountain Poison and Drug Center, Denver, CO; (2)Covance Market Access, Gaithersburg, MD; (3)Janssen Scientific Affairs, LLC, Raritan, NJ*

## **Transplant/Immunology**

225. Contributions of the Orphan Drug Act: Agents for Solid Organ Transplantation.

*Christopher R. Ensor, Pharm.D.,<sup>1</sup> Timothy R. Cote, M.D., MPH,<sup>2</sup> Lili A. Barouch, M.D.<sup>3</sup>; (1)The Johns Hopkins Hospital, Baltimore, MD; (2)Keck Graduate Institute, Claremont, CA; (3)Johns Hopkins University, Baltimore, MD*

226E. Single-Center Experience with Prospective BK Monitoring in Renal Transplantation.

*Jennifer Trofe-Clark, Pharm.D., BCPS,<sup>1</sup> Simin Goral, M.D.,<sup>2</sup> Deirdre Sawinski, M.D.,<sup>2</sup> Melissa Bleicher, M.D.,<sup>2</sup> Matthew H. Levine, M.D.,<sup>3</sup> Peter L. Abt, M.D.,<sup>3</sup> Lauren Ende-Schwartz, M.D.,<sup>4</sup> Vivanna Vandeerlin, M.D., Ph.D.,<sup>4</sup> Roy D. Bloom, M.D.<sup>2</sup>; (1)Hospital of the University of Pennsylvania, Pharmacy Services and Renal Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (2)Renal Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (3)Division of Transplant Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (4)Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, PA*

228E. Evaluation of Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Crossmatch After Desensitization.

*Shree Patel, Pharm.D., Jamie Joseph, Pharm.D., Sanjeev Akkina, M.D., James Thielke, Pharm.D., Maya Campara, Pharm.D., Patricia West-Thielke, Pharm.D., Jose Oberholzer, M.D., Enrico Benedetti, M.D.; University of Illinois Hospital and Health Sciences System, Chicago, IL*

229E. A Pharmacokinetic Comparison of a Generic Tacrolimus versus Reference in Subpopulations of Kidney Transplant Recipients.

*Jennifer Trofe-Clark, Pharm.D., BCPS,<sup>1</sup> Roy D. Bloom, M.D.,<sup>2</sup> Anne Wiland, Pharm.D., BCPS,<sup>3</sup> Basma Sadaka, Pharm.D., BCPS,<sup>4</sup> Rita R. Alloway, Pharm.D., FCCP, BCPS<sup>4</sup>;* (1)Hospital of the University of Pennsylvania, Pharmacy Services, Renal Division, Perelman School of Medicine, Univ of Pennsylvania, Philadelphia, PA; (2)Renal Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (4)Section of Transplantation, University of Cincinnati, Cincinnati, OH

230E. Evaluation of Medication Education and Adherence of Patients Being Evaluated for Kidney and/or Pancreas Transplantation.

*Tiffany R. Shin, Pharm.D.,<sup>1</sup> April Delahunty, Pharm.D., BCPS,<sup>2</sup> Holli A. Winters, Pharm.D., BCPS,<sup>2</sup> Donna M. Smolen, BSN, CNN,<sup>2</sup> Aneeka R. Qureshi, Pharm.D. Candidate,<sup>1</sup> Maria Pruchnicki, Pharm.D., BCPS, CLS<sup>1</sup>;* (1)The Ohio State University College of Pharmacy, Columbus, OH; (2)The Ohio State University Wexner Medical Center, Columbus, OH

231. Four-Year Outcomes After Corticosteroid Withdrawal in Kidney Transplant Patients: An Analysis from the Mycophenolic Acid Observational Renal Transplant Registry.

*Lonnie Smith, Pharm.D.,<sup>1</sup> Anne Wiland, Pharm.D., BCP,<sup>2</sup> V. Ram Peddi, M.D.,<sup>3</sup> Kimi Ueda, Pharm.D.<sup>3</sup>;* (1)University of Utah Hospitals and Clinics, Salt Lake City, UT; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)California Pacific Medical Center, San Francisco, CA

233. Intravenous Immunoglobulin (IVIg) as Rescue Therapy for BK Virus Nephropathy.

*Don Vu, Pharm.D., Ph.D.,<sup>1</sup> Tariq Shah, M.D.,<sup>2</sup> Robert Naraghi, M.D.,<sup>2</sup> Ian V. Hutchinson, Ph.D.,<sup>3</sup> David I. Min, Pharm.D.<sup>4</sup>;* (1)National Institute of Transplantation and Western University of Health Sciences, Los Angeles, CA; (2)National Institute of Transplantation and St. Vincent Medical Center, Los Angeles, CA; (3)USC School of Pharmacy, Los Angeles, CA; (4)Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, CA

234. Outcomes at Four Years After Kidney Transplantation in African-American Kidney Transplant Patients in the Era of Modern Immunosuppression: An Analysis from the Mycophenolic Acid Observational Renal Transplant Registry.

*Lonnie Smith, Pharm.D.,<sup>1</sup> Anne Wiland, Pharm.D., BCPS,<sup>2</sup> Ali Olyaei, Pharm.D.<sup>3</sup>;* (1)University of Utah Hospitals and Clinics, Salt Lake City, UT; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)Oregon State University and Oregon Health and Science University, Portland, OR

235. A Four-Year Analysis of Immunosuppressive Regimens and Outcomes in Expanded Criteria Donor Kidney Transplant Recipients from the Mycophenolic Acid Observational Renal Transplant Registry.

*Ali Olyaei, Pharm.D.,<sup>1</sup> V. Ram Peddi, M.D.,<sup>2</sup> Anne Wiland, Pharm.D., BCPS,<sup>3</sup> Kimi Ueda, Pharm.D.<sup>2</sup>;* (1)Oregon State University and Oregon Health and Science University, Portland, OR; (2)California Pacific Medical Center, San Francisco, CA; (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ

236. A Comparison of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil to Four Years After Kidney Transplantation: An Analysis from the Mycophenolic Acid Observational Renal Transplant Registry.

*Ali Olyaei, Pharm.D.,<sup>1</sup> Anne Wiland, Pharm.D., BCPS,<sup>2</sup> Lonnie Smith, Pharm.D.<sup>3</sup>;* (1)Oregon State University and Oregon Health and Science University, Portland, OR; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)University of Utah Hospitals and Clinics, Salt Lake City, UT

237. Thymoglobulin versus Simulect Induction in Hepatitis C Positive Kidney Transplant Recipients.

*Kwaku Marfo, Pharm.D.*,<sup>1</sup> Manhal Olaywi, M.D.,<sup>2</sup> Javier Chapochnick, M.D.,<sup>1</sup> Milan Kinkhabwala, M.D.,<sup>1</sup> Stuart Greenstein, M.D.,<sup>1</sup> Liise Kayler, M.D.,<sup>1</sup> Michele Lubetzky, M.D.,<sup>1</sup> Graciella De Boccardo, M.D.,<sup>1</sup> Enver Akalin, M.D.<sup>1</sup>; (1)Montefiore Medical Center, Bronx, NY; (2)Brooklyn Hospital Center, Brooklyn, NY

240E. Incidence of Supratherapeutic Tacrolimus Troughs Before and After Implementation of an Initial Dosing Protocol in Orthotopic Heart Transplantation.

*Tracy M. Sparkes, Pharm.D.*, Tamara Claridge, Pharm.D., BCPS, Todd A. Miano, Pharm.D., BCPS, Erin H. Ticehurst, Pharm.D., Lee R. Goldberg, M.D., MPH, FACC; Hospital of the University of Pennsylvania, Philadelphia, PA

241E. Impact of Optimization of Antiviral Therapy and Removal of Cytomegalovirus Immune Globulin on Clinical Outcomes in Liver and Combined Liver/Kidney Transplant Recipients.

*Jennifer Jebrock, Pharm.D., BCPS*,<sup>1</sup> Venessa Price, Pharm.D.<sup>1</sup>, Alexandra Centeno, Pharm.D.<sup>1</sup>, Lilian Abbo, M.D.,<sup>2</sup> Michele Morris, M.D.,<sup>2</sup> Andreas G. Tzakis, M.D.<sup>2</sup>; (1)Jackson Memorial Hospital, Miami, FL; (2)University of Miami Miller School of Medicine, Miami, FL

242. Prevention of Cytomegalovirus Disease in Moderate-Risk (D+/R+ and D-/R+) Renal Transplant Recipients Receiving Basiliximab Induction Therapy: An Efficacy and Safety Evaluation of 3 vs. 6 Months of Low-Dose Valganciclovir.

*Steven Gabardi, Pharm.D.*,<sup>1</sup> Rosemary Cross, Pharm.D.,<sup>2</sup> Kelly DePiero, Pharm.D.,<sup>3</sup> Travis B. Dick, Pharm.D., BCPS,<sup>4</sup> Pamela R. Maxwell, Pharm.D., BCPS,<sup>5</sup> Joelle Nelson, Pharm.D.,<sup>6</sup> Erin N. Newkirk, Pharm.D.,<sup>7</sup> Kathleen Nguyen, Pharm.D.,<sup>8</sup> Jeong M. Park, Pharm.D., M.S.,<sup>9</sup> Eric M. Tichy, Pharm.D., BCPS,<sup>10</sup> Kimi Ueda, Pharm.D.,<sup>11</sup> Renee Weng, Pharm.D.,<sup>12</sup> Angela Q. Maldonado, Pharm.D., BCPS<sup>13</sup>; (1)Department of Pharmacy & Renal Division, Brigham & Women's Hospital; Department of Medicine, Harvard Medical School, Boston, MA; (2)Piedmont Hospital, Atlanta, GA; (3)Lahey Clinic Medical Center, Burlington, MA; (4)Intermountain Medical Center, Murray, UT; (5)University Transplant Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; (6)University Health System, San Antonio, TX; (7)Froedtert & the Medical College of Wisconsin, Milwaukee, WI; (8)University of California Irvine Medical Center, Orange, CA; (9)University of Michigan, Ann Arbor, MI; (10)Yale-New Haven Hospital, New Haven, CT; (11)California Pacific Medical Center, San Francisco, CA; (12)UC-Irvine, Orange, CA; (13)Sacred Heart Medical Center, Spokane, WA

243. Effect of Thymoglobulin on the Development of BK Virus Viruria and Viremia in Renal Transplant Recipients: A Case-control Study.

*Allison L. Mruk, Pharm.D.*,<sup>1</sup> Yevgeniya Gokun, M.S.,<sup>2</sup> Thomas H. Waid, M.D.,<sup>1</sup> Carol Broughton, APRN,<sup>1</sup> Timothy M. Clifford, Pharm.D., BCPS<sup>1</sup>; (1)University of Kentucky Chandler Medical Center, Lexington, KY; (2)University of Kentucky College of Pharmacy, Lexington, KY

## **Women's Health**

244. Investigation of the HPV Vaccine, Gardasil: Are Patients Completing the Series as Recommended?  
*Lori Ernsthauten, Pharm.D.*, Brinda Dave, Pharm.D. Candidate, Christine Osborn, Pharm.D. Candidate, Amanda Palgut, Pharm.D. Candidate; The University of Findlay College of Pharmacy, Findlay, OH

245. Preliminary Study of FMO3, MSRA, and AOX1 Gene Polymorphisms on Pharmacokinetics of Sulindac and its Metabolites.

*Kyungeun Lee, Pharm.D.*,<sup>1</sup> Nara Lee, M.S.,<sup>1</sup> Sunny Park, B.S.,<sup>1</sup> Byungkoo Lee, Ph.D.,<sup>1</sup> Youngju Kim, M.D., Ph.D.,<sup>2</sup> Hyesun Gwak, Ph.D., Pharm.D.<sup>1</sup>; (1)Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, South Korea; (2)Department of Obstetrics and Gynecology, Ewha Womans University School of Medicine, Seoul, South Korea

## **CLINICAL PHARMACY FORUM**

These abstracts describe the delivery, development, justification, or documentation of an innovative clinical pharmacy service; they may be descriptive only and need not contain an evaluative component.

### **Cardiovascular**

265. Integration of a Pharmacist-Led Active Learning Class into the Cardiac Rehabilitation Program at a Community Hospital.

*Natalie Y. Paul, Pharm.D., BCPS; Comprehensive Pharmacy Services, Inc., Chicago, IL*

266. Reducing Heart Failure Readmissions: A Multidisciplinary Approach.

*Brian Trevarrow, Pharm.D., BCPS,<sup>1</sup> Elizabeth Purvis-Jeffrey, RN-BSN,<sup>1</sup> Paul P. Dobesh, Pharm.D., FCCP, BCPS<sup>2</sup>; (1)The Nebraska Medical Center, Omaha, NE; (2)University of Nebraska Medical Center, Omaha, NE*

267. Ability of a Clinical Pharmacist to Make Drug Therapy Interventions Using Email in Patients with Advanced Heart Failure and Ventricular-Assist Devices.

*Douglas L. Jennings, Pharm.D., BCPS (AQ-CV), Jona Lekura, Pharm.D.; Henry Ford Hospital, Detroit, MI*

268. Evaluating the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Heart Catheterizations with Proposed Protocol for Optimizing Outcomes.

*R. Naseem Amarshi, Pharm.D., M.S.,<sup>1</sup> Victoria Miller, Pharm.D.,<sup>2</sup> Friej Gobal, M.D.,<sup>1</sup> Barry Uretsky, M.D.<sup>1</sup>; (1)Central Arkansas Veterans Healthcare System, Little Rock, AR; (2)Central Arkansas Veterans Healthcare System, Little Rock, Arkansas*

### **Clinical Administration**

269. Pharmacist-Directed Rivaroxaban Prescribing in Patients Undergoing Elective Hip/Knee Replacements in a Rural, Regional Hospital in Ontario.

*Stephan Sadikian, BSP Pharm; Grey Bruce Health Services, Owen Sound, ON, Canada*

271. Justification of a Therapeutic Drug Monitoring Clinical Pharmacist Position.

*Pratish Patel, Pharm.D., David F. Gregory, Pharm.D., Bob Lobo, Pharm.D.; Vanderbilt University Medical Center, Nashville, TN*

272. Justification of a Clinical Pharmacist Position for Inpatient Anticoagulation.

*Patricia B. Miller, Pharm.D., David F. Gregory, Pharm.D., Bob Lobo, Pharm.D.; Vanderbilt University Medical Center, Nashville, TN*

### **Community Pharmacy Practice**

273. Establishing an Accredited Diabetes Self-Management Education Program Within a School of Pharmacy.

*Kayce Shealy, Pharm.D.; Presbyterian College School of Pharmacy, Clinton, SC*

### **Education/Training**

275. Development of a Clinical Operating Room Surgical Rotation.

*Michelle Holm, Pharm.D., R.Ph., John Rueter, R.Ph.; Mayo Clinic, Rochester, MN*

276. The Impact of a Pharmacist-Run Diabetes Self-Management Program on Patient Self-Management Activation and Healthy Behavior in an Underserved Patient Population.

*Laura Perry, Pharm.D., Tonya Dauterman, Pharm.D., Lori Ernsthausen, Pharm.D., Debra Parker, Pharm.D., Jenifer Kitchen, Pharm.D. Candidate, Thomas Kahle, Pharm.D. Candidate, Peter Samberg, Pharm.D. Candidate, Brett Christy, Pharm.D. Candidate; The University of Findlay College of Pharmacy, Findlay, OH*  
277. Use of the Minute Paper as a Large-Classroom Assessment Technique in Pharmacotherapy Modules.  
*Lamis Karaoui, Pharm.D., BCPS; Lebanese American University, Byblos, Lebanon*

## **Endocrinology**

281. Identifying Employees with Undiagnosed Diabetes for Participation in a Pharmacist-Run Worksite Wellness Program.

*Nicole D. Gillespie, Pharm.D., Thomas L. Lenz, Pharm.D., M.A., PAPHS, FACLM, Michael S. Monaghan, Pharm.D., BCPS; Creighton University School of Pharmacy and Health Professions, Omaha, NE*

282. Impact on Outcomes of Patients Seen by Ambulatory Care Clinical Pharmacists for Diabetes Management in a Large Public Health Care System.

*Margaret Y. Pio, Pharm.D., Marissa E. Quinones, Pharm.D., Diem H. Chow, Pharm.D., Jeffrey L. Hulstein, Pharm.D., Steven M. Boatright, Pharm.D., Elizabeth Moss, Pharm.D., Annie C. Mathew, Pharm.D.; Parkland, Dallas, TX*

283. Lessons Learned from Clinical Pharmacists' Review of Glucometer Download Reports in the Primary Care Setting.

*Craig D. Logemann, Pharm.D.,<sup>1</sup> Nicholas P. Lehman, Pharm.D.,<sup>2</sup> Carrie F. Koenigsfeld, Pharm.D.,<sup>2</sup> Ginelle A. Bryant, Pharm.D.<sup>2</sup>; (1)Iowa Health Physicians and Clinics, Des Moines, IA; (2)Iowa Health Physicians and Clinics and Drake University, Des Moines, IA*

284. Pharmacist-Led Diabetes Collaborative Drug Therapy Management Program Improves Glycemic Control in Patients with Uncontrolled T2DM Treated with Insulin.

*Carrie McAdam-Marx, Ph.D., R.Ph.,<sup>1</sup> Brandon T. Jennings, Pharm.D.,<sup>2</sup> Arati Dahal, Ph.D.,<sup>3</sup> Karen Gunning, Pharm.D.<sup>4</sup>; (1)University of Utah College Pharmacotherapy Outcomes Research Center, Salt Lake City, UT; (2)University of Utah College of Pharmacy, Salt Lake City, UT; (3)University of Utah Pharmacotherapy Outcomes Research Center, Salt Lake City, UT; (4)Departments of Pharmacotherapy & Family and Preventive Medicine, Salt Lake City, UT*

## **Family Medicine**

285. Implementation of New FDA-Mandated Dose Limitations with Simvastatin in an Outpatient Family Medicine Clinic.

*Ila M. Harris, Pharm.D.,<sup>1</sup> Ann M. Philbrick, Pharm.D.,<sup>2</sup> Christopher J. Fallert, M.D.<sup>1</sup>; (1)University of Minnesota Medical School, St. Paul, MN; (2)University of Minnesota College of Pharmacy, Minneapolis, MN*

## **Geriatrics**

287E. An Innovative Collaborative Practice for Clinical Pharmacists in an Interdisciplinary, Primary Care-Based Memory Clinic in Ontario, Canada.

*Carlos Rojas-Fernandez, Pharm.D., Tejal Patel, Pharm.D., Linda Lee, M.D.; University of Waterloo School of Pharmacy & Centre for Family Medicine, Kitchener, ON, Canada*

288. Documentation of Home-Based Primary Care Pharmacist Interventions.

*Virginia Krause, Pharm.D.,<sup>1</sup> Bridget Kaufmann, Pharm.D.,<sup>2</sup> Kara Wong, Pharm.D.<sup>1</sup>; (1)VA Puget Sound Health System, Seattle, WA; (2)VA Puget Sound Health Care System, Seattle, WA*

## **Oncology**

306. Results of a Pharmacy-Driven Erythropoietin-Stimulating Agent Dispensing and Monitoring Program at a Community Hospital.

*Anay Moscu, Pharm.D.,<sup>1</sup> Maria C. Figueroa, Pharm.D.,<sup>2</sup> Jorge Garcia, Pharm.D.<sup>3</sup>*; (1)Baptist Hospital of Miami, Miami, FL; (2)Baptist Hospital of Miami, FL; (3)Baptist Hospital of Miami, Kendall, FL

## **Transplant/Immunology**

319. Cytomegalovirus (CMV) IgG Quantification and Risk of CMV Disease in Seropositive Renal Transplant Recipients with Seropositive Donors.

*Joelle Nelson, Pharm.D.*; University Health System, San Antonio, TX

321. Modification of Induction in Kidney Transplants with Pre-transplant Viral Infection or Chronic Long-term Immunosuppression.

*Jennifer Deyo, Pharm.D.,<sup>1</sup> Robert Dupuis, Pharm.D., BCPS,<sup>2</sup> RuthAnn M. Lee, Pharm.D., CPP,<sup>2</sup> Tomasz Kozlowski, M.D.<sup>3</sup>*; (1)University of North Carolina Memorial Hospital – Department of Pharmacy, Chapel Hill, NC; (2)UNC Eshelman School of Pharmacy, Chapel Hill, NC; (3)UNC Memorial Hospital – Division of Abdominal Transplant, Chapel Hill, NC

## **Women's Health**

322. Implications on Vaccine Compliance Rates in an Obstetrics and Gynecology Outpatient Clinic with the Implementation of a Pharmacist Driven Vaccination Assessment: Phase 2.

*Alicia B. Forinash, Pharm.D., BCPS, BCACP, Jamie M. Pitlick, Pharm.D., BCPS, Abigail M. Yancey, Pharm.D., BCPS*; St. Louis College of Pharmacy, St. Louis, MO

## **LATE BREAKERS**

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoconomics, and pharmacoepidemiology.

## **Adult Medicine**

440. A Hospital's Effort to Lower the Readmission of Patients with Heart Failure (help-hf): A Pilot Study.

*Pamela M. Moye, Pharm.D., BCPS,<sup>1</sup> Paul Douglass, M.D.,<sup>2</sup> Phillip S. Owen, Pharm.D., BCPS,<sup>1</sup> Teresa Pounds, Pharm.D., BCNSP<sup>2</sup>*; (1)Mercer University College of Pharmacy and Health Sciences, Atlanta, GA; (2)Atlanta Medical Center, Atlanta, GA

## **Ambulatory Care**

441. Prescribing Patterns for the Outpatient Treatment of Constipation, Irritable Bowel Syndrome–Related Constipation and Opioid-Induced Constipation.

*Katy E. Trinkley, Pharm.D.,<sup>1</sup> Bruce Sill, Pharm.D., M.S.,<sup>2</sup> Kyle Porter, MAS,<sup>3</sup> Milap C. Nahata, Pharm.D., M.S.<sup>4</sup>*; (1)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; (2)Takeda Pharmaceuticals International, Inc., Glastonbury, CT; (3)Ohio State University Center for Biostatistics, Columbus, OH; (4)Ohio State University College of Pharmacy, Columbus, OH

442. A Retrospective Chart Review of the Standard of Asthma Care in a Primary Care Teaching Clinic.

*Lindsay A. Sorge, Pharm.D., Chrystian R. Pereira, Pharm.D.*; University of Minnesota College of Pharmacy, Minneapolis, MN

## Cardiovascular

443. Effects on Warfarin Dosage Requirements After Anticoagulation Therapy with Dabigatran.  
*Beth H. Brubaker, Pharm.D., Kristy Lucas, Pharm.D., Mike Broce, B.A.; University of Charleston School of Pharmacy, Charleston, WV*

## Community Pharmacy Practice

444. Impact of Medicare Part D on Community Pharmacy: A Multi-region, Multi-state Survey.  
*Shamima Khan, MBA, Ph.D.; Western New England University, Springfield, MA*

## Education/Training

445. Evaluation of a Lecture on Hospice Care for Pharm.D. Students.  
*Cara L. McDermott, Pharm.D., M.S., Dana P. Hammer, R.Ph., Ph.D.; University of Washington School of Pharmacy, Seattle, WA*

446E. Impact of a Student Pharmacist–Driven Medication History Service.  
*Lynette R. Moser, Pharm.D.,<sup>1</sup> Justine S. Gortney, Pharm.D.,<sup>1</sup> Josh Raub, Pharm.D.,<sup>2</sup> Kim Claeys, Pharm.D.<sup>1</sup>;*  
(1)Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI;  
(2)Detroit Receiving Hospital/University Health Center, Detroit, MI

## Emergency Medicine

447. Outcomes Associated with Emergency Department Pharmacists' Participation in Antimicrobial Stewardship.  
*Stephanie Z. Kujawski, Pharm.D., Bethany S. Delk, Pharm.D., BCPS; Mission Hospitals, Asheville, NC*

## Oncology

448. Cancer Adverse Events Associated with Dipeptidyl Peptidase 4 Inhibitors: Data Mining of Public FDA Adverse Event Reporting System.  
*Xiaodong Feng, Ph.D., Pharm.D., Amie Cai, B.S., Kevin Dong, Pharm.D. Student, Nilesh Bhutada, Ph.D., John Inciardi, Pharm.D., D.Sci.; California Northstate University College of Pharmacy, Rancho Cordova, CA*

## Pediatrics

449. Modeling and Simulation to Predict the Pharmacokinetics of Intravenous Cefazolin in Children—A Strategy to Reduce the Number of Pediatric Subjects in Pharmacokinetic Studies.  
*Felix Siegel, Ph.D.,<sup>1</sup> Christopher M. Rubino, Pharm.D., BCPS,<sup>2</sup> Rebecca A. Stolarick, B.S.,<sup>1</sup> Patricia A. Smith, B.S.,<sup>1</sup> Martin Unverdorben, M.D., Ph.D.<sup>1</sup>;* (1)B. Braun Medical Inc., Allentown, PA; (2)Institute for Clinical Pharmacodynamics, Latham, NY

## Pharmacoeconomics/Outcomes

450. Increasing Medication Core Measures Compliance Utilizing Unit-Based Clinical Pharmacists.  
*Lindsay I. Varga, Pharm.D., BCPS, Elizabeth Marino Sabo, Pharm.D., BCPS, Jacqueline M. von Vital, Pharm.D., Suzanne Y. Brown, M.S., R.Ph.; Pennsylvania Hospital, Philadelphia, PA*

## Infectious Diseases



452. Adequacy of Empiric Coverage for Gram-negative Bacteremias in an Adult Population.

*Branden Nemecek, Pharm.D.*, Nicole Bohm, Pharm.D., and Juanmanuel Gomez, M.D.; Medical University of South Carolina, Charleston, SC

453. Impact of Antibiotic Selection on Risk-Adjusted Mortality in ICU Patients Requiring Gram-negative Therapy.

*John S. Esterly, Pharm.D.*,<sup>1</sup> Jean A. Patel, Pharm.D.,<sup>2</sup> Milena McLaughlin, Pharm.D.,<sup>3</sup> Curtis H. Weiss, M.D., M.S.,<sup>4</sup> Richard G. Wunderink, M.D.,<sup>4</sup> Kristin March, Pharm.D.,<sup>2</sup> Craig Cooper, Pharm.D.,<sup>4</sup> Erik Rachwalski, Pharm.D.,<sup>4</sup> and Michael J. Postelnick, BSPHarm<sup>4</sup>; (1)Chicago State University College of Pharmacy, Chicago, IL. (2)Northwestern Memorial Hospital, Chicago, IL. (3)Midwestern University Chicago College of Pharmacy, Downers Grove, IL. (4)Northwestern University Feinberg School of Medicine, Chicago, IL

455. Impact of an Evidence-Based Pharmacotherapy Elective on Performance During the Fourth Professional Year.

Nathan Pinner, Pharm.D., BCPS,<sup>1</sup> and Jessica Starr, Pharm.D., BCPS<sup>2</sup>

(1)Auburn University Harrison School of Pharmacy, Tuscaloosa, AL, (2)Auburn University Harrison School of Pharmacy, Birmingham, AL

456. Comparison of Serum Cystatin C versus Serum Creatinine in Predicting Vancomycin Trough Levels in Patients with Reduced Muscle Mass.

*Douglas D. DeCarolis, Pharm.D.*,<sup>1</sup> Joey Thorson, Pharm.D.,<sup>2</sup> Rebecca Marraffa, Pharm.D.,<sup>3</sup> and Megan A. Clairmont, Pharm.D.<sup>4</sup>; (1)Minneapolis VA Medical Center, Minneapolis, MN, (2)Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, (3)Memorial Hermann – Pharmacy Wellness Clinic, Houston, TX, (4)Minneapolis Veteran Affairs Health Care System, Minneapolis, MN